Edwards(EW) EVOQUE, two-year clinical trials show "almost complete elimination of tricuspid regurgitation"… survival rates and quality of life improve simultaneously

Edwards Lifesciences (EW) reports that 2-year follow-up clinical results show that its transcatheter tricuspid valve replacement system “EVOQUE” has almost eliminated tricuspid regurgitation while improving patients’ survival rates and quality of life, drawing growing market attention.

According to TRISCEND II 2-year data announced by Edwards Lifesciences (EW) on the 26th (local time) at the American College of Cardiology (ACC.26) in the United States, the EVOQUE system has maintained stable therapeutic effects over the long term. Based on the study results, post-operative tricuspid regurgitation improved to a level that was nearly resolved, and patients’ health status and quality of life were also significantly enhanced.

Safety is especially worth noting. The company emphasized that no additional device-related risks were observed, and in analyses that included cross-over patients, overall mortality was also reduced. This has been interpreted as the significance extending beyond symptom improvement, with positive outcomes also achieved on survival metrics.

The EVOQUE system previously delivered positive data at the 18-month time point, which was presented by the European Society of Cardiology (ESC). Similar effects were also confirmed in real-world clinical settings. In addition, consistent improvements were observed in the STS/ACC TVT registry data, which included more than 1,000 patients, further strengthening the credibility of the treatment.

Edwards Lifesciences (EW) said that the EVOQUE system has now received approvals in both the United States and Europe. Against the backdrop of the rapid expansion of the structural heart disease treatment market, this set of long-term data is expected to enhance the commercial potential and clinical value of transcatheter valve therapy technologies.